08 April 2009
Christopher Spillane
Pfizer's research operations will be split into two separate organisations following the completion of its $68 billion acquisition of Wyeth. In the sweeping overhaul, the US firm's biopharmaceutical research will be divided into traditional drug discovery, and biotech and vaccines.
The...
Please Login to read the full article.
RELATED CONTENT
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
